Knopp Biosciences to Present Data Characterizing Its Potassium Channel Activator Candidate for the Treatment of KCNQ2 Epileptic Encephalopathy at the American Epilepsy Society’s 2019 Annual Meeting
27.11.2019 14:00:00 EET | Business Wire | Press release
Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases with high unmet need, today announced that data from its Kv7 platform will be presented at the American Epilepsy Society’s (AES) 2019 Annual Meeting from December 6-10 in Baltimore.
“We look forward to sharing progress on our lead drug candidate for the treatment of KCNQ2 epileptic encephalopathy as we advance the understanding of ion channel activators and the important role they play in epilepsy and other neurological conditions with high unmet need,” said Michael Bozik, M.D., Chief Executive Officer of Knopp Biosciences.
Ion channels are proteins that regulate the excitability of cells, and drugs that modulate ion channels play an important role in treating a variety of neurological and smooth muscle conditions. Among ion channel targets, potassium channels play a key role in the pathophysiology of epilepsy and other unmet needs in diseases of the nervous system. Knopp is advancing a library of Kv7.2/7.3 channel activators to modulate this key ion channel in nerve cells, targeting a devastating genetic mutation associated with neonatal encephalopathy, as well as other rare epilepsies and neuropathic pain.
Details related to Knopp Biosciences’ AES abstracts and poster presentations can be found in the table below.
Follow Knopp Biosciences on Twitter via @KnoppBio and keep up to date with AES Annual Meeting news and updates using the hashtag #AES2019.
|
Abstract Title |
Abstract Number / Presentation Details |
|
Discovery and Characterization of KB-3061: A Potent Kv7.2/7.3 Ion Channel Activator for the Treatment of KCNQ2-Neonatal Epileptic Encephalopathy |
Abstract 3.045: Poster Presentation
|
|
KB-3061 is a Potent Activator of Wild Type KCNQ Channels and Restores Current to KCNQ2 Encephalopathy Variants In Vitro
|
Abstract 3.047: Poster Presentation
|
ABOUT KNOPP BIOSCIENCES LLC
Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases of high unmet need. Knopp’s clinical-stage small molecule, dexpramipexole, is in Phase 2 clinical trials for severe eosinophilic asthma. Knopp’s preclinical Kv7 platform is directed to small molecule treatments for neonatal epileptic encephalopathy, other rare epilepsies, and neuropathic pain. Please visit www.knoppbio.com.
Knopp's Kv7 research is supported under Award Number U44NS093160 and Award Number U44NS115732 of the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH). The content of this announcement is solely the responsibility of Knopp and does not necessarily represent the views of the NIH.
This press release contains "forward-looking statements," including statements relating to planned regulatory filings and clinical development programs. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that any investigational drug product will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market a product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing clinical study to verify their safety and effectiveness.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191127005157/en/
Contact information
Media inquiries:
Kate Coyle
kate.coyle@icrinc.com
203-682-8210
Surabhi Verma
surabhi.verma@icrinc.com
646-677-1825
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Estée Lauder Companies and Jo Malone London Launch Experience That Turns Visual Taste into a Personalized Fragrance Wardrobe, exclusively on Pinterest17.6.2026 16:26:00 EEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) and Jo Malone London today announced the launch of Scent Scanner, a first-of-its-kind experience available exclusively on Pinterest and rolling out in the US and France. The experience translates the visual preferences people have expressed across their Pinterest boards into personalized Jo Malone London fragrance recommendations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260617962807/en/ Building on the success of Jo Malone London's AI Scent Advisor, introduced in 2025, Scent Scanner offers a new way for consumers to find their personalized scent, shifting the starting point from words to images. While the AI Scent Advisor invited consumers to describe the scent they were seeking, Scent Scanner reads visual inspiration – imagery, color palettes, textures, destinations, rituals and aesthetics – to suggest fragrances suited to each individual. The custom Pinterest experience bri
Azul Addresses the Java Runtime Security Blind Spot Autonomous AI Can Now Exploit17.6.2026 16:00:00 EEST | Press release
Azul, the trusted leader in enterprise Java for today’s AI and cloud-first world, today launched a free JVM vulnerability risk assessment to address the blind spot that autonomous AI exploitation tools are increasingly able to find. With mean time to exploit (MTTE) collapsing from months to days or hours, the unmanaged Java estate has become an urgent enterprise security vulnerability. Azul’s assessment gives DevOps and SecOps teams complete visibility into the hidden risks embedded in the runtime of their Java estate before threat actors get there first, and is designed to complement the broader security, licensing and compliance solutions and services delivered by Azul’s trusted partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260617352753/en/ Azul's JVM Vulnerability Risk Assessment dashboard. The Threat Landscape Has Transformed For most of Java’s enterprise history, a sophisticated exploit required a sophisticat
Hologic’s New Sustainability Report Marks 40 Years of Impact17.6.2026 16:00:00 EEST | Press release
Hologic, Inc., a global leader in women’s health, today released its 2025 Sustainability Report. The new report coincides with Hologic’s 40th anniversary and underscores how the company’s longstanding purpose — to enable healthier lives for women everywhere, every day — continues to drive progress for patients, communities and the planet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260617160174/en/ Hologic 2025 Sustainability Report “We have always firmly believed that our success as a company is fundamentally tied to our ability and commitment to help women worldwide live healthier lives,” said Sharon Vidal, Chief Sustainability Officer at Hologic. “Together with our customers and partners, we’re taking measurable steps to increase global access to innovative medical technologies while pursuing a more sustainable and equitable future for all.” Hologic’s Sustainability Report details progress on environmental sustainabili
Fortegra Strengthens Actuarial Leadership with Appointment of Anthony Katz as SVP, Reserving17.6.2026 16:00:00 EEST | Press release
The Fortegra Group, Inc., a global specialty insurer, today announced the appointment of Anthony Katz as Senior Vice President, Reserving. Mr. Katz will lead Fortegra’s team of professional actuaries, with responsibility for reserving, credit insurance, statistical reporting, and key initiatives including IFRS 17. “Anthony brings more than 30 years of actuarial expertise and a genuine commitment to building the capabilities our distribution partners depend on,” said Rick Kahlbaugh, Chief Executive Officer at Fortegra. “His background across reserving, actuarial transformation, and international markets will be instrumental as we continue to support our distribution partners.” A credentialed actuary holding FCAS, FSA, and MAAA designations, Mr. Katz brings more than 30 years of experience across reserving, pricing, and actuarial transformation. He has held senior leadership roles at ToaRe, Everest Re, Arch Insurance, Ernst & Young, and ACE, and most recently served as an independent con
Hitachi Expands Its Work With OpenAI to Accelerate AI-Driven Modernization and Cybersecurity17.6.2026 16:00:00 EEST | Press release
Hitachi, Ltd. (TSE:6501, "Hitachi") today announced that it will expand its work with OpenAI*1 to accelerate AI-driven modernization and cybersecurity. The work combines OpenAI’s frontier AI technology with Hitachi’s domain expertise and know-how in supporting mission-critical systems and social infrastructure to accelerate AI transformation (AX) for customers and society. Working together, the two companies’ FDE teams will leverage OpenAI’s AI agent “Codex” to analyze the source code of mission-critical legacy systems and work to establish an AI-driven modernization approach that supports safe migration through enhanced visibility into system design. Based on this approach, Hitachi aims to develop solutions to support the modernization of core systems and to roll them out sequentially across a wide range of industries, starting with financial institutions. Hitachi also plans to gain access to OpenAI’s AI models for cybersecurity through OpenAI’s “Trusted Access for Cyber (TAC)”.*2 As
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom